Sargramostim (Leukine) — Clinical FAQs

Question 1

What is Sargramostim FDA-approved to treat?

Accepted Answer

Sargramostim is FDA-approved for the following oncology indications: 1. Acceleration of myeloid reconstitution after autologous bone marrow transplantation in patients with AML (first complete remission), NHL, and Hodgkin disease 2. Acceleration of myeloid reconstitution after allogeneic bone marrow transplantation — in case of graft failure or engraftment delay 3. Mobilization of peripheral blood progenitor cells (PBPCs) for autologous transplantation 4. Post-PBPC transplantation: acceleration of myeloid reconstitution 5. Treatment of acute myeloid leukemia (AML) in older adults following induction chemotherapy — to shorten time to neutrophil recovery and reduce infection-related morbidity (and 1 additional indications).

Question 2

How does Sargramostim work (mechanism of action)?

Accepted Answer

Recombinant yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF). Binds the GM-CSF receptor (GMR), a heterodimeric cytokine receptor expressed on myeloid progenitor cells, granulocytes, monocytes, macrophages, dendritic cells, and endothelial cells, activating JAK2/STAT5, PI3K/AKT, and MAPK signaling. Unlike filgrastim (G-CSF, stimulates only the neutrophil lineage), sargramostim promotes proliferation and differentiation of multiple myeloid lineages — granulocytes (neutrophils, eosinophils), monocytes/macrophages, and dendritic cells — providing broader myeloid reconstitution. Also activates mature granulocytes and macrophages for enhanced phagocytosis, oxidative burst, and ADCC activity. Mobilizes hematopoietic stem/progenitor cells from bone marrow into peripheral blood for apheresis collection.

Question 3

How is Sargramostim administered?

Accepted Answer

Sargramostim is administered Intravenous (IV) or Subcutaneous (SC). Post-transplant reconstitution: 250 mcg/m²/day IV over 2 h (or SC) starting 2–4 h after bone marrow infusion and ≥24 h after last dose of chemotherapy; continue until post-nadir ANC ≥1500/mm³ for 3 consecutive days or maximum 42 days.

Question 4

What are the most common side effects of Sargramostim?

Accepted Answer

The most commonly reported side effects of Sargramostim (≥10% incidence) include: Fever and flu-like symptoms (most common — especially with IV infusion), Bone pain and arthralgias, Diarrhea and nausea, Peripheral edema, Injection site reactions (SC) and others (7 total). Consult your oncologist for complete prescribing information.

Question 5

Is Sargramostim safe during pregnancy?

Accepted Answer

Sargramostim pregnancy safety: Category C — no adequate well-controlled studies in pregnant women; use only if potential benefit justifies risk.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Sargramostim — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms